Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free ALMR Stock Alerts

Alamar Biosciences (ALMR) Competitors

$32.14 -1.08 (-3.25%)
As of 04:00 PM Eastern
Compare

ALMR vs. BRKR, QGEN, CAI, STVN, and SHC

Should you buy Alamar Biosciences stock or one of its competitors? Alamar Biosciences's main competitors and comparable companies include Bruker (BRKR), Qiagen (QGEN), Caris Life Sciences (CAI), Stevanato Group (STVN), and Sotera Health (SHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Alamar Biosciences compare to Bruker?

Bruker (NASDAQ:BRKR) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Alamar Biosciences has a net margin of 0.00% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Bruker-2.35% 12.47% 4.91%
Alamar Biosciences N/A N/A N/A

79.5% of Bruker shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bruker has higher revenue and earnings than Alamar Biosciences. Bruker is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bruker$3.44B2.65-$8.60M-$0.70N/A
Alamar Biosciences$74.21M30.05-$29.82M-$1.96N/A

Bruker currently has a consensus price target of $57.00, indicating a potential downside of 4.47%. Alamar Biosciences has a consensus price target of $31.80, indicating a potential downside of 1.06%. Given Alamar Biosciences' higher probable upside, analysts clearly believe Alamar Biosciences is more favorable than Bruker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bruker
2 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.43
Alamar Biosciences
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Bruker had 9 more articles in the media than Alamar Biosciences. MarketBeat recorded 9 mentions for Bruker and 0 mentions for Alamar Biosciences. Bruker's average media sentiment score of 0.55 beat Alamar Biosciences' score of 0.00 indicating that Bruker is being referred to more favorably in the media.

Company Overall Sentiment
Bruker Positive
Alamar Biosciences Neutral

Summary

Bruker beats Alamar Biosciences on 11 of the 15 factors compared between the two stocks.

How does Alamar Biosciences compare to Qiagen?

Qiagen (NYSE:QGEN) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Qiagen had 8 more articles in the media than Alamar Biosciences. MarketBeat recorded 8 mentions for Qiagen and 0 mentions for Alamar Biosciences. Qiagen's average media sentiment score of 0.62 beat Alamar Biosciences' score of 0.00 indicating that Qiagen is being referred to more favorably in the media.

Company Overall Sentiment
Qiagen Positive
Alamar Biosciences Neutral

Qiagen has a net margin of 19.49% compared to Alamar Biosciences' net margin of 0.00%. Qiagen's return on equity of 14.47% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Qiagen19.49% 14.47% 8.34%
Alamar Biosciences N/A N/A N/A

Qiagen presently has a consensus target price of $43.51, indicating a potential downside of 0.58%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential downside of 1.06%. Given Qiagen's higher probable upside, equities analysts plainly believe Qiagen is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen
0 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.43
Alamar Biosciences
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Qiagen has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qiagen$2.09B4.31$424.88M$1.9522.44
Alamar Biosciences$74.21M30.05-$29.82M-$1.96N/A

Summary

Qiagen beats Alamar Biosciences on 13 of the 14 factors compared between the two stocks.

How does Alamar Biosciences compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Alamar Biosciences has lower revenue, but higher earnings than Caris Life Sciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caris Life Sciences$812.03M11.01-$68.09M$0.3687.92
Alamar Biosciences$74.21M30.05-$29.82M-$1.96N/A

In the previous week, Caris Life Sciences had 14 more articles in the media than Alamar Biosciences. MarketBeat recorded 14 mentions for Caris Life Sciences and 0 mentions for Alamar Biosciences. Caris Life Sciences' average media sentiment score of 0.40 beat Alamar Biosciences' score of 0.00 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Caris Life Sciences Neutral
Alamar Biosciences Neutral

Caris Life Sciences has a net margin of 10.62% compared to Alamar Biosciences' net margin of 0.00%. Caris Life Sciences' return on equity of 18.77% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Caris Life Sciences10.62% 18.77% 9.34%
Alamar Biosciences N/A N/A N/A

Caris Life Sciences presently has a consensus price target of $26.50, suggesting a potential downside of 16.27%. Alamar Biosciences has a consensus price target of $31.80, suggesting a potential downside of 1.06%. Given Alamar Biosciences' higher probable upside, analysts clearly believe Alamar Biosciences is more favorable than Caris Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caris Life Sciences
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46
Alamar Biosciences
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Summary

Caris Life Sciences beats Alamar Biosciences on 10 of the 13 factors compared between the two stocks.

How does Alamar Biosciences compare to Stevanato Group?

Alamar Biosciences (NASDAQ:ALMR) and Stevanato Group (NYSE:STVN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Stevanato Group has a net margin of 10.99% compared to Alamar Biosciences' net margin of 0.00%. Stevanato Group's return on equity of 10.43% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alamar BiosciencesN/A N/A N/A
Stevanato Group 10.99%10.43%6.16%

Alamar Biosciences presently has a consensus price target of $31.80, indicating a potential downside of 1.06%. Given Alamar Biosciences' higher probable upside, equities analysts plainly believe Alamar Biosciences is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alamar Biosciences
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Stevanato Group
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.86

Stevanato Group has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alamar Biosciences$74.21M30.05-$29.82M-$1.96N/A
Stevanato Group€1.34B4.88€158.21M€0.5638.61

In the previous week, Stevanato Group had 1 more articles in the media than Alamar Biosciences. MarketBeat recorded 1 mentions for Stevanato Group and 0 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.00 equaled Stevanato Group'saverage media sentiment score.

Company Overall Sentiment
Alamar Biosciences Neutral
Stevanato Group Neutral

Summary

Stevanato Group beats Alamar Biosciences on 10 of the 13 factors compared between the two stocks.

How does Alamar Biosciences compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Sotera Health has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sotera Health$1.16B4.49$77.94M$0.5732.09
Alamar Biosciences$74.21M30.05-$29.82M-$1.96N/A

In the previous week, Sotera Health had 2 more articles in the media than Alamar Biosciences. MarketBeat recorded 2 mentions for Sotera Health and 0 mentions for Alamar Biosciences. Sotera Health's average media sentiment score of 0.58 beat Alamar Biosciences' score of 0.00 indicating that Sotera Health is being referred to more favorably in the media.

Company Overall Sentiment
Sotera Health Positive
Alamar Biosciences Neutral

Sotera Health currently has a consensus price target of $21.50, indicating a potential upside of 17.55%. Alamar Biosciences has a consensus price target of $31.80, indicating a potential downside of 1.06%. Given Sotera Health's stronger consensus rating and higher possible upside, research analysts plainly believe Sotera Health is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sotera Health
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.73
Alamar Biosciences
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Sotera Health has a net margin of 13.44% compared to Alamar Biosciences' net margin of 0.00%. Sotera Health's return on equity of 40.12% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sotera Health13.44% 40.12% 7.55%
Alamar Biosciences N/A N/A N/A

91.0% of Sotera Health shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Sotera Health beats Alamar Biosciences on 14 of the 15 factors compared between the two stocks.

Get Alamar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALMR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALMR vs. The Competition

Export
MetricAlamar BiosciencesLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.23B$10.52B$7.21B$13.10B
Dividend YieldN/A1.45%2.53%13.00%
P/E Ratio-16.4073.29274.5825.69
Price / Sales30.05108.39648.7885.88
Price / CashN/A27.6076.3152.02
Price / BookN/A5.8210.446.32
Net Income-$29.82M$56.67B$3.49B$359.73M
7 Day Performance9.39%4.39%0.51%1.35%
1 Month Performance-6.13%2.47%-3.38%-3.68%
1 Year PerformanceN/A28.33%16.04%5.56%

Alamar Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALMR
Alamar Biosciences
1.1219 of 5 stars		$32.14
-3.3%		$31.80
-1.1%		N/A$2.23B$74.21MN/A222
BRKR
Bruker
2.0116 of 5 stars		$61.39
-2.6%		$57.00
-7.2%		+86.7%$9.35B$3.44BN/A11,085
QGEN
Qiagen
3.8091 of 5 stars		$43.37
-2.3%		$43.51
+0.3%		-9.3%$8.93B$2.09B22.235,654
CAI
Caris Life Sciences
2.9727 of 5 stars		$29.98
-3.0%		$26.50
-11.6%		N/A$8.47B$812.03M83.281,846
STVN
Stevanato Group
2.1157 of 5 stars		€21.66
-4.5%		N/A-19.7%€6.57B€1.34B38.686,010

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ALMR) was last updated on 9/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel